Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Medical Physics|December 11, 2013
Investigation of the effects of cell model and subcellular location of gold nanoparticles on nuclear dose enhancement factors using Monte Carlo simulationZhongli Cai, Jean-Philippe Pignol, Niladri Chattopadhyay, et al.
Molecular Pharmaceutics|September 25, 2015
Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)LuSimmyung Yook, Zhongli Cai, Yijie Lu, et al.
Nuclear Medicine and Biology|February 17, 2020
Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [<sup>64</sup>Cu]Cu-NOTA-panitumumab F(ab')<sub>2</sub> alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparibAmanda J Boyle, Ping-Jiang Cao, Zhongli Cai, et al.
Molecular Pharmaceutics|October 27, 2010
Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancerNiladri Chattopadhyay, Zhongli Cai, Jean-Philippe Pignol, et al.
EJNMMI Radiopharmacy and Chemistry|August 12, 2021
Dose predictions for [<sup>177</sup>Lu]Lu-DOTA-panitumumab F(ab')<sub>2</sub> in NRG mice with HNSCC patient-derived tumour xenografts based on [<sup>64</sup>Cu]Cu-DOTA-panitumumab F(ab')<sub>2</sub> - implications for a PET theranostic strategyAnthony Ku, Misaki Kondo, Zhongli Cai, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 18, 2008
Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGFZhongli Cai, Zhuo Chen, Kristy E Bailey, et al.
Breast Cancer Research and Treatment|June 28, 2012
¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancerAisha Fasih, Humphrey Fonge, Zhongli Cai, et al.
Molecular Pharmaceutics|October 26, 2022
<sup>90</sup>Y-Labeled Gold Nanoparticle Depot (NPD) Combined with Anti-PD-L1 Antibodies Strongly Inhibits the Growth of 4T1 Tumors in Immunocompetent Mice and Induces an Abscopal Effect on a Distant Non-Irradiated TumorZhongli Cai, Rella Liu, Conrad Chan, et al.
Pharmaceutical Research|December 18, 2016
Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with <sup>177</sup>LuZhongli Cai, Simmyung Yook, Yijie Lu, et al.
Nuclear Medicine and Biology|October 28, 2016
<sup>111</sup>In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injectionZhongli Cai, Niladri Chattopadhyay, Kaiyu Yang, et al.
Pageof 6